Cargando…

The GRPR Antagonist [(99m)Tc]Tc-maSSS-PEG(2)-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity

Gastrin-releasing peptide receptors (GRPRs) are overexpressed in the majority of primary prostate tumors and in prostatic lymph node and bone metastases. Several GRPR antagonists were developed for SPECT and PET imaging of prostate cancer. We previously reported a preclinical evaluation of the GRPR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abouzayed, Ayman, Borin, Jesper, Lundmark, Fanny, Rybina, Anastasiya, Hober, Sophia, Zelchan, Roman, Tolmachev, Vladimir, Chernov, Vladimir, Orlova, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178091/ https://www.ncbi.nlm.nih.gov/pubmed/37175001 http://dx.doi.org/10.3390/diagnostics13091611

Ejemplares similares

Preclinical Evaluation of (99m)Tc-Labeled GRPR Antagonists maSSS/SES-PEG(2)-RM26 for Imaging of Prostate Cancer
por: Abouzayed, Ayman, et al.
Publicado: (2021)

Phase I Trial of [(99m)Tc]Tc-maSSS-PEG(2)-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors
por: Chernov, Vladimir, et al.
Publicado: (2023)

(66)Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [(66)Ga]Ga-NOTA-PEG(2)-RM26
por: Rinne, Sara S., et al.
Publicado: (2021)

Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer
por: Abouzayed, Ayman, et al.
Publicado: (2020)

Phase I Clinical Trial Using [(99m)Tc]Tc-1-thio-D-glucose for Diagnosis of Lymphoma Patients
por: Chernov, Vladimir, et al.
Publicado: (2022)

Phase I clinical evaluation of (99m)Tc-labeled Affibody molecule for imaging HER2 expression in breast cancer
por: Bragina, Olga, et al.
Publicado: (2023)

Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [(99m)Tc]Tc-ADAPT6 and [(99m)Tc]Tc-(HE)(3)-G3, for Imaging of HER2-Positive Breast Cancer
por: Bragina, Olga, et al.
Publicado: (2023)

Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer
por: Mitran, Bogdan, et al.
Publicado: (2019)

Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer—Optimization of the Affinity towards PSMA by Linker Modification in Murine Model
por: Lundmark, Fanny, et al.
Publicado: (2020)

[(99m)Tc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2020)

High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26
por: Mitran, Bogdan, et al.
Publicado: (2017)

Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart
por: Oroujeni, Maryam, et al.
Publicado: (2019)

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer
por: Abouzayed, Ayman, et al.
Publicado: (2019)

Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist (177)Lu‐DOTAGA‐PEG(2)‐RM26
por: Mitran, Bogdan, et al.
Publicado: (2019)

Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26
por: Mitran, Bogdan, et al.
Publicado: (2019)

Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [(68)Ga]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation
por: Lundmark, Fanny, et al.
Publicado: (2023)

Phase I Trial of (99m)Tc-(HE)(3)-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer
por: Bragina, Olga, et al.
Publicado: (2022)

Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer
por: Baun, Christina, et al.
Publicado: (2020)

Body TC correlación RM
Publicado: (1999)

Study of Binding Kinetics and Specificity of (99m)Tc-SSS-Complex and (99m)Tc-HMPAO to Blood Cells
por: Auletta, S., et al.
Publicado: (2018)

Body TC con correlación RM
Publicado: (2007)

[(99m)Tc]Tc-DB15 in GRPR-Targeted Tumor Imaging with SPECT: From Preclinical Evaluation to the First Clinical Outcomes
por: Nock, Berthold A., et al.
Publicado: (2021)

Imágenes normales de TC y RM /
por: Möller, Torsten B.
Publicado: (2000)

Optimal composition and position of histidine-containing tags improves biodistribution of (99m)Tc-labeled DARPin G3
por: Vorobyeva, Anzhelika, et al.
Publicado: (2019)

(99m)Tc-labeled nanocolloid drugs: development methods
por: Sadkin, Vladimir, et al.
Publicado: (2020)

Atlas de anatomía por TC y RM /
Publicado: (1995)

Preclinical Evaluation of (99m)Tc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake
por: Oroujeni, Maryam, et al.
Publicado: (2021)

(99m)Tc-labeled monosaccharide kits: development methods and quality control
por: Stasyuk, Elena, et al.
Publicado: (2020)

Imágenes por RM y TC del sistema musculoesquelético /
Publicado: (1993)

Direct In Vivo Comparison of (99m)Tc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy
por: Tolmachev, Vladimir, et al.
Publicado: (2022)

(177)Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry
por: Abouzayed, Ayman, et al.
Publicado: (2023)

Localization of (99m)Tc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses
por: Kaloudi, Aikaterini, et al.
Publicado: (2019)

Visualization of epithelial cell adhesion molecule-expressing renal cell carcinoma xenografts using designed ankyrin repeat protein Ec1 labelled with (99m)Tc and (125)I
por: Tolmachev, Vladimir, et al.
Publicado: (2022)

Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with (99m)Tc for Radionuclide Imaging of HER2 Expression in Cancer
por: Larkina, Mariia, et al.
Publicado: (2022)

Influence of composition of cysteine-containing peptide-based chelators on biodistribution of (99m)Tc-labeled anti-EGFR affibody molecules
por: Oroujeni, Maryam, et al.
Publicado: (2018)

In Vitro and In Vivo Evaluation of a (18)F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging
por: Varasteh, Zohreh, et al.
Publicado: (2013)

Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with (99m)Tc using a peptide-based cysteine-containing chelator
por: Andersson, Ken G., et al.
Publicado: (2016)

Evaluation of (99m)Tc-Z(IGF1R:4551)-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression
por: Mitran, Bogdan, et al.
Publicado: (2014)

Comparison of [(99m)Tc]Tc-tilmanocept with [(99m)Tc]Tc-sulphur colloids and [(99m)Tc]Tc-albumin colloids for sentinel lymph node detection in patients with cutaneous malignancies of the head
por: Ooms, Mark, et al.
Publicado: (2022)

Clinical usefulness of (99m)Tc-HYNIC-TOC, (99m)Tc(V)-DMSA, and (99m)Tc-MIBI SPECT in the evaluation of pituitary adenomas
por: Vukomanovic, Vladimir R., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_939arg04752sijhccbjtplvtk5